PMV PharmaceuticalsPMVP
PMVP
About: PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Employees: 63
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
0% more call options, than puts
Call options by funds: $20K | Put options by funds: $20K
3.21% less ownership
Funds ownership: 78.95% [Q2] → 75.75% (-3.21%) [Q3]
12% less capital invested
Capital invested by funds: $65.8M [Q2] → $58.1M (-$7.68M) [Q3]
20% less funds holding
Funds holding: 93 [Q2] → 74 (-19) [Q3]
23% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 30
79% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 24
Research analyst outlook
We haven’t received any recent analyst ratings for PMVP.
Financial journalist opinion
Positive
Zacks Investment Research
6 months ago
Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher
PMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Neutral
GlobeNewsWire
6 months ago
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma's rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation.
Neutral
Business Wire
6 months ago
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
BOSTON & PRINCETON, N.J.--(BUSINESS WIRE)--Foundation Medicine and PMV Pharma partner to develop FoundationOne®CDx as a companion diagnostic for PMV Pharma's rezatapopt.
Neutral
GlobeNewsWire
7 months ago
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
Neutral
GlobeNewsWire
9 months ago
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
PRINCETON, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that the first patient has been dosed in the registrational, tumor-agnostic PYNNACLE Phase 2 trial of rezatapopt (PC14586) in patients with advanced solid tumors harboring a TP53 Y220C mutation and KRAS wild-type (WT). Rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets mutated p53 Y220C proteins in solid tumors.
Neutral
GlobeNewsWire
9 months ago
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer
PRINCETON, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that a Phase 1 analysis reported promising anti-tumor activity of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation. Rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets the TP53 Y220C mutation in solid tumors.
Neutral
GlobeNewsWire
9 months ago
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
Neutral
GlobeNewsWire
11 months ago
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
PRINCETON, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced a strategic reduction of its workforce by approximately 30%. PMV will maintain a focused discovery research effort and expects that the resulting savings in operating expenses will extend its cash runway to the end of 2026.
Neutral
GlobeNewsWire
11 months ago
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced key appointments across its leadership team. These include:
Positive
Seeking Alpha
1 year ago
PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price
PMV Pharmaceuticals' phase 1/2 trial of its drug, PC14586, in solid tumors with a Y220C p53 mutation produced initial data in 2022, but the response was mixed. A 2023 update on data from the phase 1/2 trial is a net positive, in my opinion, with confirmation of the benefit of PC14586 in more patients. PMVP is enrolling a combination study of PC14586 with pembrolizumab, which could expand the addressable market for the drug and provide a 2024 catalyst.
Charts implemented using Lightweight Charts™